The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Clinical outcomes of patients with WM treated with bortezomib in the UK R2W study
Shirley D’Sa, MD, FRCP, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, summarizes the findings of the UK R2W trial (NCT01592981) comparing the efficacy of bortezomib, cyclophosphamide and rituximab versus dexamethasone, cyclophosphamide and rituximab in patients with Waldenström’s macroglobulinemia (WM). This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen- speaker fees, research grants, congress support, advisory boards
BeiGene- speaker fees, research grants, congress support, advisory boards
Sanofi- speaker fees, advisory boards
